October 2017

Home  /  2017  /  October

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma